person · Reporting owner

Haller Julia A

Disclosed activity across 4 companies

Tapewire entity: 14549
SEC CIK: 0001656082

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BRISTOL MYERS SQUIBB COBMY · Entity 1662	Director	June 15, 2026	June 16, 2026
HYPERION DEFI, INC.EYEN · Entity 7220	Director	June 16, 2022	June 21, 2022
Outlook Therapeutics, Inc.OTLK · Entity 608	Director	October 01, 2025	October 04, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BRISTOL MYERS SQUIBB CO

Report date June 15, 2026 · Filed June 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.10 par valueSEC Table I · non-derivative	Direct	34,079	Reported balance After 2026-06-15 transaction · row 1 1 source row Row 1 · 2026-06-15 · Exercise / conversion · Acquired 20,460 · Balance 34,079
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.76 · Expires 2026-06-15	Direct	0	Reported balance After 2026-06-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-15 · Exercise / conversion · Disposed 20,460 · Balance 0 F1: The reporting person made a cash exercise of an option and is currently holding the underlying shares. F2: All of the shares are currently exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person made a cash exercise of an option and is currently holding the underlying shares.

F2: All of the shares are currently exercisable.

HYPERION DEFI, INC.

Report date June 16, 2022 · Filed June 21, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $.0001SEC Table I · non-derivative	Direct	30,408	Reported balance After 2022-06-16 transaction · row 1 1 source row Row 1 · 2022-06-16 · Grant · Acquired 22,222 · Balance 30,408 F1: Represents restricted stock units that fully vest on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2032-06-16	Direct	30,769	Reported balance After 2022-06-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-06-16 · Grant · Acquired 30,769 · Balance 30,769 F2: The option becomes exercisable on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that fully vest on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.

F2: The option becomes exercisable on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.

Outlook Therapeutics, Inc.

Report date October 01, 2025 · Filed October 04, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2035-10-01	Direct	286,734	Reported balance After 2025-10-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-10-01 · Grant · Acquired 286,734 · Balance 286,734 F1: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2035-10-03	Direct	58,648	Reported balance After 2025-10-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-10-03 · Grant · Acquired 58,648 · Balance 58,648 F2: The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Filing footnotes · ownership attribution and instrument terms

F1: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

F2: The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CELGENE CORP /DE/

Report date November 20, 2019 · Filed November 22, 2019

Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-11-20 transaction · row 1 1 source row Row 1 · 2019-11-20 · Disposition to issuer · Disposed 2,409 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $117.53 · Expires 2025-10-15	Direct	Reported balance After 2019-11-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.98 · Expires 2026-06-15	Direct	Reported balance After 2019-11-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-20 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.04 · Expires 2027-06-14	Direct	Reported balance After 2019-11-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-20 · Disposition to issuer · Disposed 10,500 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13	Direct	Reported balance After 2019-11-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-20 · Disposition to issuer · Disposed 300 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-20 · Disposition to issuer · Disposed 970 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.

F2: This option was fully exercisable.

F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.

F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 15, 2026 Filed Jun 16, 2026 20:07 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	20,460	$0.00 Strike: $53.76	$0.00	Disclosure SEC source: 0001656082-26-000004 · wk-form4_1781640443.xml · derivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 20,460 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person made a cash exercise of an option and is currently holding the underlying shares. F2 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
June 15, 2026 Filed Jun 16, 2026 20:07 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	20,460	$53.76	$1,099,929.60	Disclosure SEC source: 0001656082-26-000004 · wk-form4_1781640443.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 01, 2026 Filed Feb 3, 2026 21:22 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	3,996.367	$55.05	$220,000.00	Disclosure SEC source: 0001656082-26-000002 · wk-form4_1770153750.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,903.154 Underlying: Common Stock, $0.10 par value · 3,996.367 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
October 03, 2025 Filed Oct 4, 2025 00:12 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	58,648	$0.00 Strike: $1.06	$0.00	Disclosure SEC source: 0001649989-25-000009 · primary_doc.xml · derivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,648 Underlying: Common Stock · 58,648 shares Expires 2035-10-03 F2 · derivative.exercise_date: The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document
October 01, 2025 Filed Oct 4, 2025 00:12 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	286,734	$0.00 Strike: $1.04	$0.00	Disclosure SEC source: 0001649989-25-000009 · primary_doc.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,734 Underlying: Common Stock · 286,734 shares Expires 2035-10-01 F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document
February 01, 2025 Filed Feb 5, 2025 00:13 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	3,562.341	$58.95	$210,000.00	Disclosure SEC source: 0000014272-25-000020 · wk-form4_1738714429.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,223.091 Underlying: Common Stock, $0.10 par value · 3,562.341 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
October 03, 2024 Filed Oct 4, 2024 00:30 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	12,082	$0.00 Strike: $5.25	$0.00	Disclosure SEC source: 0001415889-24-024708 · form4-10032024_081015.xml · derivative · entry 3 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,082 Underlying: Common Stock · 12,082 shares Expires 2034-10-03 F3 · derivative.exercise_date: The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document
October 01, 2024 Filed Oct 4, 2024 00:30 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	47,232	$0.00 Strike: $5.22	$0.00	Disclosure SEC source: 0001415889-24-024708 · form4-10032024_081015.xml · derivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,232 Underlying: Common Stock · 47,232 shares Expires 2034-10-01 F2 · derivative.exercise_date: This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document
October 01, 2024 Filed Oct 4, 2024 00:30 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	56,636	$0.00 Strike: $5.22	$0.00	Disclosure SEC source: 0001415889-24-024708 · form4-10032024_081015.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,636 Underlying: Common Stock · 56,636 shares Expires 2034-10-01 F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document
March 07, 2024 Filed Mar 8, 2024 21:30 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	94,441	$0.00 Strike: $0.41	$0.00	Disclosure SEC source: 0001415889-24-007354 · form4-03082024_090336.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,441 Underlying: Common Stock · 94,441 shares Expires 2034-03-07 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document
February 01, 2024 Filed Feb 6, 2024 00:17 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	4,314.773	$48.67	$210,000.00	Disclosure SEC source: 0000014272-24-000028 · wk-form4_1707178628.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,341.22 Underlying: Common Stock, $0.10 par value · 4,314.773 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
December 31, 2023 Filed Jan 3, 2024 22:36 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	706.49	$51.31	$36,250.00	Disclosure SEC source: 0000014272-24-000006 · wk-form4_1704321375.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,746.04 Underlying: Common Stock, $0.10 par value · 706.49 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
October 04, 2023 Filed Oct 5, 2023 21:15 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	210,225	$0.00 Strike: $0.24	$0.00	Disclosure SEC source: 0001209191-23-052240 · doc4.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,225 Underlying: Common Stock · 210,225 shares Expires 2033-10-04 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $44,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document
September 30, 2023 Filed Oct 3, 2023 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	624.569	$58.04	$36,249.98	Disclosure SEC source: 0000014272-23-000163 · wk-form4_1696372274.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,797.26 Underlying: Common Stock, $0.10 par value · 624.569 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
June 30, 2023 Filed Jul 5, 2023 21:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	553.943	$63.95	$35,424.65	Disclosure SEC source: 0000014272-23-000136 · wk-form4_1688592700.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,978.355 Underlying: Common Stock, $0.10 par value · 553.943 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
March 31, 2023 Filed Apr 5, 2023 00:37 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	486.943	$69.31	$33,750.02	Disclosure SEC source: 0000014272-23-000091 · wf-form4_168065505897640.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,255.615 Underlying: Common Stock, $0.10 par value · 486.943 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
March 29, 2023 Filed Mar 31, 2023 21:49 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	41,065	$0.00 Strike: $1.05	$0.00	Disclosure SEC source: 0001209191-23-021912 · doc4.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,065 Underlying: Common Stock · 41,065 shares Expires 2033-03-29 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document
February 01, 2023 Filed Feb 4, 2023 00:19 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	2,807.806	$71.23	$200,000.02	Disclosure SEC source: 0000014272-23-000034 · wf-form4_167546993071782.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,768.672 Underlying: Common Stock, $0.10 par value · 2,807.806 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
December 31, 2022 Filed Jan 4, 2023 22:25 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	469.076	$71.95	$33,750.02	Disclosure SEC source: 0000014272-23-000016 · wf-form4_167287111139496.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,826.219 Underlying: Common Stock, $0.10 par value · 469.076 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
October 05, 2022 Filed Oct 7, 2022 20:35 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	42,239	$0.00 Strike: $1.25	$0.00	Disclosure SEC source: 0001209191-22-053117 · doc4.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,239 Underlying: Common Stock · 42,239 shares Expires 2032-10-05 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $44,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2023, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document
September 30, 2022 Filed Oct 5, 2022 01:16 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	474.75	$71.09	$33,749.98	Disclosure SEC source: 0000014272-22-000188 · wf-form4_166493247570386.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,244.249 Underlying: Common Stock, $0.10 par value · 474.75 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
August 11, 2022 Filed Aug 15, 2022 21:16 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $1.15	$0.00	Disclosure SEC source: 0001209191-22-045826 · doc4.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-08-11 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in three equal installments on each of August 11, 2023, August 11, 2024 and August 11, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document
June 30, 2022 Filed Jul 5, 2022 20:28 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	438.312	$77.00	$33,750.02	Disclosure SEC source: 0000014272-22-000155 · wf-form4_165705289311290.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,654.671 Underlying: Common Stock, $0.10 par value · 438.312 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
June 16, 2022 Filed Jun 21, 2022 18:28 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	GrantStock Option (right to buy) · Derivative	30,769	$0.00 Strike: $1.80	$0.00	Disclosure SEC source: 0001415889-22-006810 · form4-06212022_110633.xml · derivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,769 Underlying: Common Stock · 30,769 shares Expires 2032-06-16 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document
June 16, 2022 Filed Jun 21, 2022 18:28 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	GrantCommon Stock, par value $.0001	22,222	$0.00	$0.00	Disclosure SEC source: 0001415889-22-006810 · form4-06212022_110633.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,408 F1 · shares: Represents restricted stock units that fully vest on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document
June 03, 2022 Filed Jun 7, 2022 21:50 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	2,949	$0.00	$0.00	Disclosure SEC source: 0000014272-22-000124 · wf-form4_165463859067171.xml · derivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 2,949 shares Expires 2022-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F1 · derivative.exercise_date: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F1 · derivative.expiration_date: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. Read SEC document
June 03, 2022 Filed Jun 7, 2022 21:50 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	2,949	$0.00	$0.00	Disclosure SEC source: 0000014272-22-000124 · wf-form4_165463859067171.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F2 · price: Each restricted stock unit converts into one share of common stock upon vesting. Read SEC document
March 31, 2022 Filed Apr 4, 2022 22:14 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	462.139	$73.03	$33,750.01	Disclosure SEC source: 0000014272-22-000106 · wf-form4_164911044680593.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,107.698 Underlying: Common Stock, $0.10 par value · 462.139 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
February 01, 2022 Filed Feb 3, 2022 23:04 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	3,067.955	$65.19	$199,999.99	Disclosure SEC source: 0000014272-22-000041 · wf-form4_164392945981410.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,645.559 Underlying: Common Stock, $0.10 par value · 3,067.955 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
December 31, 2021 Filed Jan 4, 2022 23:21 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	521.251	$62.35	$32,500.00	Disclosure SEC source: 0000014272-22-000015 · wf-form4_164133847930961.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,482.489 Underlying: Common Stock, $0.10 par value · 521.251 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
November 17, 2021 Filed Nov 22, 2021 14:22 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	GrantStock Option (right to buy) · Derivative	9,653	$0.00 Strike: $3.59	$0.00	Disclosure SEC source: 0001415889-21-005367 · form4-11222021_061159.xml · derivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,653 Underlying: Common Stock · 9,653 shares Expires 2031-11-17 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document
November 17, 2021 Filed Nov 22, 2021 14:22 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	GrantCommon Stock, par value $.0001	6,963	$0.00	$0.00	Disclosure SEC source: 0001415889-21-005367 · form4-11222021_061159.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,186 F1 · shares: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document
September 30, 2021 Filed Oct 1, 2021 20:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	549.265	$0.00	$0.00	Disclosure SEC source: 0000014272-21-000219 · wf-form4_163312027292644.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,870.465 Underlying: Common Stock, $0.10 par value · 549.265 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
June 30, 2021 Filed Jul 1, 2021 21:16 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	486.998	$0.00	$0.00	Disclosure SEC source: 0000014272-21-000174 · wf-form4_162517416071414.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,247.38 Underlying: Common Stock, $0.10 par value · 486.998 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
June 13, 2021 Filed Jun 14, 2021 22:56 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	902	$0.00	$0.00	Disclosure SEC source: 0000014272-21-000149 · wf-form4_162371135343506.xml · derivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 902 shares Expires 2021-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. F1 · derivative.expiration_date: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. F1 · derivative.underlying: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. Read SEC document
June 13, 2021 Filed Jun 14, 2021 22:56 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	902	$0.00	$0.00	Disclosure SEC source: 0000014272-21-000149 · wf-form4_162371135343506.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. F2 · price: Each restricted stock unit converts into one share of common stock upon vesting. Read SEC document
June 03, 2021 Filed Jun 4, 2021 20:35 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	2,949	$0.00	$0.00	Disclosure SEC source: 0000014272-21-000144 · wf-form4_162283893698433.xml · derivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,949 Underlying: Common Stock, $0.10 par value · 2,949 shares Expires 2022-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F1 · derivative.exercise_date: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F1 · derivative.expiration_date: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. Read SEC document
June 03, 2021 Filed Jun 4, 2021 20:35 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	2,949	$0.00	$0.00	Disclosure SEC source: 0000014272-21-000144 · wf-form4_162283893698433.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F2 · price: Each restricted stock unit converts into one share of common stock upon vesting. Read SEC document
March 31, 2021 Filed Apr 1, 2021 23:29 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	GrantStock Option (right to buy) · Derivative	1,637	$0.00 Strike: $5.11	$0.00	Disclosure SEC source: 0001638599-21-000395 · doc4_7182.xml · derivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,637 Underlying: Common Stock · 1,637 shares Expires 2031-03-31 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of March 31, 2022 or the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document
March 31, 2021 Filed Apr 1, 2021 23:29 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	GrantCommon Stock, par value $.0001	1,223	$0.00	$0.00	Disclosure SEC source: 0001638599-21-000395 · doc4_7182.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,223 F1 · shares: Represents restricted stock units that vest on the earlier of March 31, 2022 or the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document
March 31, 2021 Filed Apr 2, 2021 17:16 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	514.811	$63.13	$32,500.02	Disclosure SEC source: 0000014272-21-000118 · wf-form4_161738372741256.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,689.564 Underlying: Common Stock, $0.10 par value · 514.811 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
February 01, 2021 Filed Feb 4, 2021 00:17 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	3,054.171	$62.21	$189,999.98	Disclosure SEC source: 0000014272-21-000050 · wf-form4_161239784937177.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,174.753 Underlying: Common Stock, $0.10 par value · 3,054.171 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
December 31, 2020 Filed Jan 6, 2021 01:11 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	523.94	$62.03	$32,500.00	Disclosure SEC source: 0000014272-21-000020 · wf-form4_160989544623329.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,072.75 Underlying: Common Stock, $0.10 par value · 523.94 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
September 30, 2020 Filed Oct 2, 2020 20:30 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	539.061	$60.29	$32,499.99	Disclosure SEC source: 0000014272-20-000264 · wf-form4_160167062234972.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,507.151 Underlying: Common Stock, $0.10 par value · 539.061 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
June 30, 2020 Filed Jul 2, 2020 21:07 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	528.893	$58.80	$31,098.91	Disclosure SEC source: 0000014272-20-000218 · wf-form4_159372397567975.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,930.548 Underlying: Common Stock, $0.10 par value · 528.893 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
June 14, 2020 Filed Jun 16, 2020 21:15 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	558	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000194 · wf-form4_159234213031831.xml · derivative · entry 4 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 558 shares Expires 2020-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F3 · shares: One June 14, 2017, the reporting person was granted 1,674 restricted stock units, vesting in three equal installments beginning on June 14, 2018. F3 · derivative.exercise_date: One June 14, 2017, the reporting person was granted 1,674 restricted stock units, vesting in three equal installments beginning on June 14, 2018. F3 · derivative.expiration_date: One June 14, 2017, the reporting person was granted 1,674 restricted stock units, vesting in three equal installments beginning on June 14, 2018. Read SEC document
June 14, 2020 Filed Jun 16, 2020 21:15 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	558	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000194 · wf-form4_159234213031831.xml · nonDerivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: One June 14, 2017, the reporting person was granted 1,674 restricted stock units, vesting in three equal installments beginning on June 14, 2018. F2 · price: Each restricted stock unit converts into one share of common stock upon vesting. Read SEC document
June 13, 2020 Filed Jun 16, 2020 21:15 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	903	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000194 · wf-form4_159234213031831.xml · derivative · entry 3 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902 Underlying: Common Stock, $0.10 par value · 903 shares Expires 2021-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. F1 · derivative.exercise_date: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. F1 · derivative.expiration_date: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. Read SEC document
June 13, 2020 Filed Jun 16, 2020 21:15 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	903	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000194 · wf-form4_159234213031831.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. F2 · price: Each restricted stock unit converts into one share of common stock upon vesting. Read SEC document
June 03, 2020 Filed Jun 5, 2020 20:39 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	2,949	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000176 · wf-form4_159138957133577.xml · derivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,898 Underlying: Common Stock, $0.10 par value · 2,949 shares Expires 2022-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F1 · derivative.exercise_date: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F1 · derivative.expiration_date: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.